RedHill Biopharma Secures 5-Year Market Exclusivity for Talicia® with FDA Grant

RedHill Biopharma has been granted five years of market exclusivity by the FDA for its drug Talicia, which is used to treat H. pylori infection. This grant is in addition to the three years of exclusivity already granted. Talicia is protected by intellectual property rights until 2034. The drug is the leading first-line therapy prescribed by U.S. gastroenterologists for H. pylori eradication and has demonstrated high efficacy and tolerability. The FDA recently approved a change in the dosing regimen for Talicia, which may improve patient adherence and treatment outcomes.